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Short title: (Thujone in Artemisia vulgaris poisoning)  30 
 31 
Abstract  32 
Plants of the Artemisia genus are used worldwide as ingredients of botanical preparations. 33 
This paper describes the case of a 49-year-old man admitted to the emergency room at a 34 
Zurich hospital in a manic state after the ingestion of 1 L of an infusion of Artemisia vulgaris. 35 
Two monoterpenic ketones, α- and β-thujone, are present in various concentrations in 36 
Artemisia spp, but adverse effects have previously been associated only with essential oil 37 
from Artemisia absinthium and attributed to the inhibition of gamma-aminobutyric acid 38 
receptors, with consequent excitation and convulsions. 39 
The aim of this work was to examine and quantify the possible presence of thujone in the 40 
patient's serum and urine. A High Performance Liquid Chromatography (HPLC) method with 41 
isocratic separation and fluorescence detection (FLD) was set up and validated. Serum 42 
thujone concentrations were found to be 27.7±3.48 μg/mL at day 0 and 24.1±0.15 μg/mL on 43 
day 1. Results were confirmed by a gas chromatography with flame ionization detection (FID).  44 
Poisoning due to thujone was thus confirmed, suggesting four possible scenarios: 1) an 45 
unusually high concentration of thujone in the Artemisia vulgaris ingested; 2) chronic 46 
exposure as the cause of the poisoning; 3) low metabolic efficiency of the patient; 4) 47 
contamination or adulteration of the plant material with other Artemisia species, e.g. Artemisia 48 
absinthium.  49 
Practical application 50 
These results could aid research in the field of adverse effects of botanicals, lead to better 51 
understanding and management of similar cases of poisoning, and promote more informed 52 
use of natural products. 53 
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Introduction 59 
Artemisia vulgaris L. (mugwort) is a weed in the family of Asteraceae, widely distributed in 60 
Europe, Asia and North America. Its traditional use is mainly based on infusions with 61 
supposed antihypertensive, antispasmodic, anti-inflammatory and anthelmintic properties 62 
(Miller, 2000). Other applications have been suggested in the field of gynecology 63 
(dysmenorrhea and problems during labor)  (Chevallier, 1996; Lee et al. 1998). Artemisia 64 
vulgaris was used as a flavor in beers before hops, and infusions of the leaves and flowering 65 
tops have been prescribed for digestive problems (Barney and Di Tommaso, 2003; Miller, 66 
2000). The genus Artemisia is highly variable in morphology and phytochemical composition 67 
– approximately 60 different compounds have been identified  in it (Abad, Bedoja, Apaza, and 68 
Bermejo, 2012). Thujone is a monoterpenic ketone naturally present in two stereoisomeric 69 
forms: (-)-3-isothujone (CAS 546-80-5) or -thujone and (+)-3-isothujone (CAS 471-15-8)or -70 
thujone  (O'Neil, 2013). Figure 1 shows their chemical structures.  71 
Thujone occurs in different quantities in Artemisia species. Its toxicological potential was 72 
emphasized by EMA (European Medicines Agency) in its monograph on both Artemisia 73 
absinthium L. herba (EMA, 2009a) and Salvia officinalis L. folium: “Thujone is reported to be 74 
neurotoxic and chemotypes with low content of thujone should be preferred. The intake of 75 
thujone should not exceed 3.0 mg/day” (EMA, 2009b). The content of - and -thujone in 76 
Artemisia vulgaris L. is normally below the levels found in Artemisia absinthium L., but the 77 
concentration is variable (Pelkonen, Abass, and Wiesner, 2013). The essential oil from the 78 
herbal stem and flowers of Artemisia vulgaris L. contain approximately 56.3% -thujone and 79 
7.5% -thujone (EFSA, 2012) but, because of their low solubility in water, it is difficult to 80 
predict the quantity extracted by traditional infusion.  81 
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-thujone and -thujone are both responsible for neurotoxic effects, -thujone being 3-4 82 
times as potent as -thujone (Höld, Sirisoma, and Casida, 2001). The neurotoxicity is due to 83 
the rapid action of thujone in modulating the GABA-gated chloride channels and accounts for 84 
the epileptiform convulsions that are usually present in cases of acute poisoning (EMA, 2012). 85 
Convulsions are normally preceded by other less specific symptoms, such as vasodilation 86 
leading to hypotension, tachycardia and respiratory problems (IPCS, 1981). 87 
Some case reports of severe intoxication due to the consumption of herbal preparations 88 
containing thujone have been published. Blindness, hallucinations and epileptiform 89 
convulsions sometimes progressing to unconsciousness are the most usual clinical patterns 90 
described (Burkhard, Brukhardt, Haenggeli, and Landis, 1999; Holstege, Baylor, and 91 
Rusyniak, 2002; Lachenmeier, Walch, Padosch, and Kröner, 2006; Strang, Arnold, and 92 
Peters, 1999). Acute poisoning due to thujone is most frequently associated with the 93 
consumption of Artemisia absinthium L. and alcoholic beverages containing its essential oil. 94 
Like other famous artists, Vincent Van Gogh suffered from absinthism, which differs from 95 
alcoholism in presenting episodes of delirium and epilepsy (Arnold, 1988; Holstege et al. 96 
2002).  97 
The acute oral toxicity (LD50) of thujone in laboratory animals (mouse, rat, guinea pig) has 98 
been reported at doses between 192 and 500 mg/kg body weight (EMA, 2012; SCF, 2002). In 99 
a study performed in rats, where thujone was administered by gavage on five days a week for 100 
13 weeks, a NOEL (no-observed effect level) of 12.5 mg/kg bw for convulsion was 101 
established in males (Surber, 1962). In a similar study, where thujone was administered by 102 
gavage 6 times/week for 14 weeks, the NOEL for convulsive effect was 10 mg/kg bw in males 103 
and 5 mg/kg bw in females (Margaria, 1963). In 2-year studies performed by the National 104 
Toxicology Program (NTP, 2011) a NOEL for mortality of 12.5 mg/kg bw was identified in rats 105 
(although clonic seizures were observed at this level - the lowest administered), while in mice 106 
a NOEL for both mortality and seizure was established at 12 mg/kg bw. 107 
Few data on the pharmacokinetic and toxicokinetic of thujone in humans are available. Max 108 
(1990) reported that a dose of 2-4 mg of thujone (0.03-0.06 mg/kg body weight), consumed 109 
with an alcoholic drink, did not induce the acute effects described in the scientific literature. 110 
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Hinkelbein (2004) confirmed that a dose of 3.5 mg of thujone, corresponding to 0.05 mg/kg 111 
bw, should be safe. 112 
In 2012, EMA published a statement on the use of herbs containing thujone with the 113 
evaluation of acute and chronic toxicity of thujone in humans (EMA, 2012). The conclusions 114 
were that animal studies can be considered significant in calculating the human sensitivity to 115 
thujone, even though a direct extrapolation of the dose responsible for acute poisoning is 116 
uncertain. According to the available data, daily doses of 1.5-3.85 mg would not produce 117 
neurological disorders, while doses of 15 mg could affect attention and mood. In agreement, 118 
Dettling, Grass, Schuff, Skopp, Strohbeck-Kuehner, and Haffner (2004) showed that the 119 
intake of 17-20 mg in a person of 70 kg bw (0.24-0.28 mg/kg bw day) could be responsible for 120 
mild effects, such as problems in driving or operating machinery. On the basis of these results, 121 
EMA indicated 3 mg as the maximum safe daily dose for humans (EMA, 2009a).  122 
 123 
The study reported in this paper describes a case of poisoning, which occurred in a 49-year-124 
old man presenting a manic state after the ingestion of 1 L of Artemisia vulgaris infusion. The 125 
specific clinical symptoms suggested poisoning by thujone and this was confirmed by its 126 
presence in the patient's serum and urine. Two analytical approaches were used: 1) a newly 127 
developed and validated HPLC-FLD method, and 2) a published method based on gas 128 
chromatography coupled with a flame ionization detector (FID).  129 
 130 
 131 
Case report 132 
A 49-year-old man was admitted to the University Hospital of Zurich in a manic state. 133 
According to the patient, he was habitually drank 1 L/day of an infusion prepared from 134 
Artemisia vulgaris. There were no details on how the infusion was prepared, but he had 135 
continued the practice for about three years. 136 
Blood samples were taken on the day of admission (day 0) and on the following day 137 
(day 1), while urine was sampled only on day 1. Approval from an ethics committee or 138 
institutional review board was not necessary for the analyses performed, since they had been 139 
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requested to establish the source of the poisoning. The patient gave Informed consent for 140 
publication of this case. 141 
 142 
Materials and methods 143 
Purified standards  144 
The purified standard of α,β-thujone (80% purity; 70% α-thujone and 10% β-thujone) was 145 
from Sigma Aldrich (Steinheim, Germany). This mixture was the product with the highest 146 
quality available in the short time necessitated by the patient’s condition and its standard of 147 
purity was considered sufficient for our purposes.  148 
Reagents 149 
The reagents (LC grade) were: acetone  (Farmitalia Carlo Erba, Milano, Italy); L-ascorbic acid 150 
(Sigma-Aldrich, Steinheim, Germany); acetonitrile, methanol and water (VWR International, 151 
Fontenay-sous-Bois, France). 152 
 153 
HPLC-FLD METHOD 154 
Preparation of standard solutions and calibration curve 155 
The reference standard solution contained 0.724 g/mL of α and β-thujone (taking into 156 
consideration purity of 80.0% and density 0.925 g/mL). An aliquot of 10 µL of the standard 157 
solution was diluted in 10 mL of methanol to a final concentration of 0.724 mg/mL. Standard 158 
solutions were added to a healthy volunteer’s serum (“control” sample) to concentrations of 159 
14.5, 29.0, 57.9 and 72.4 µg/mL of thujone. 160 
Preparation of biological samples  161 
Aliquots of 700 μL of the patient’s and control serum (the latter without and with the addition 162 
of purified thujone) were added to 20 μL of an aqueous solution of L-ascorbic acid (1% w/v), 163 
used as a preservative; 700 μL of acetone was added to each and the resulting solutions 164 
were thoroughly vortexed and centrifuged at 2500 r.c.f. for 5 minutes (Hermle Labortechnik, 165 
Wehingen, Germany). The supernatants were filtered through a 0.45 μm syringe filter (VWR 166 
Iternational, Fontenay-sous-Bois, France) and injected into the HPLC. 167 
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The urine sample was filtered as such on a 0.45 μm filter and injected into the 168 
chromatographic equipment. 169 
Chromatographic conditions 170 
For the identification and quantification of thujone in the patient’s serum, a specific HPLC 171 
method combined with fluorimetric detection was developed. This method proved incapable 172 
of separating the two isomers, but this was achieved by gas chromatography, see below. The 173 
equipment consisted of an Intelligent PU-880 pump (Jasco, Tokyo, Japan), a fluorescence 174 
detector FP-1520 (Jasco, Tokyo, Japan), a sample injection valve Rheodyne 7725 with 20 µL 175 
loop (Cotati, California, USA) and a column LiChrospher® 100, RP-8, 250 x 4 mm, particle 176 
size 5 µm (Merck KGaA, Darmstadt, Germany) heated at 30 °C. ChromNAV software (Jasco, 177 
Tokyo, Japan) was used for data integration. The analysis was performed by isocratic elution 178 
at a flow rate of 1 mL/min with a mobile phase containing acetonitrile:water 55:45 (v/v). The 179 
fluorescence detector was set at 220/290 nm (λex/λem). 180 
Method validation 181 
The HPLC method was validated according to internationally recognized guidelines for 182 
analytical methods (FDA, 2013; Peters, Drummer, and Musshoff, 2007; Shabir, 2003). The 183 
following parameters were calculated: system suitability test (SST), linearity, sensitivity as 184 
LOD (Limit of Detection) and LOQ(Limit of Quantitation), selectivity, accuracy and precision. 185 
GC-FID 186 
Chromatographic conditions 187 
Gas-chromatographic analyses were performed according to Dybowski and Dawidowicz 188 
(2016) with some modifications. The equipment included a DANI 8610 gas-chromatograph 189 
(DANI Instruments, Cologno Monzese, Italy) with a flame ionization detector (DANI 86/10, 190 
DANI Instruments, Cologno Monzese, Italy). For chromatographic separation of α- and β-191 
thujone and an internal standard, naphthalene, a Supelco SLB®-5ms fused silica capillary 192 
column (length 30 m, i.d. 0.25 mm, df 0.25 μm) was used (Sigma-Aldrich, Steinheim, 193 
Germany). Helium was used as a carrier. The injector temperature was set at 290 °C. The 194 
oven temperature program employed was: 1 min at 50 °C followed by an increase of 6 °C/min 195 
up to 110 °C and then at a rate of 20 °C/min up to 280 °C.  196 
Preparation of standard solutions and calibration curve 197 
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A calibration curve was prepared by injecting solutions of purified α- and β-thujone in the 198 
presence of naphthalene as an internal standard (ISTD) (Sigma-Aldrich, Steinheim, 199 
Germany). Standard solutions were prepared by diluting the commercial standard in 200 
dichloromethane. The final concentrations were: for α-thujone 109, 52, 42, 18, 1 g/mL; and 201 
for β-thujone 20, 10, 8.3, 0.2 g/mL. Internal standard concentration was 25 g/mL in all the 202 
samples. Two microliters of the sample were injected into the GC at least three times. 203 
Sample preparation 204 
Sample preparation was modified from the original method, since the biological fluids most 205 
usually received by emergency rooms are serum (not  plasma) and urine. Dichloromethane 206 
(200 L), containing 25 g/mL of ISTD, was added to 200 L serum and the two phases were 207 
subjected to vortex mixing for one minute. The resultant emulsion was centrifuged at 2500 208 
r.c.f. for 5 minutes. The upper aqueous phase was then separated and extracted again with 209 
200 L dichloromethane containing ISTD. The organic layers were combined and analyzed. 210 
RESULTS  211 
The patient arrived at the emergency room in a manic state. He reported a habit of drinking 212 
(daily and in large quantity) an infusion of Artemisia vulgaris. The clinical symptoms 213 
presented by the patient were compatible with an exposure to thujone, a neurotoxic molecule 214 
contained in variable quantity in Artemisia spp, but normally hardly present in Artemisia 215 
vulgaris (Abad et al. 2012). 216 
To test the hypothesis that thujone was responsible for the observed poisoning, thujone was 217 
quantified in the patient's serum and urine by HPLC-FLD and by gas chromatography coupled 218 
with FID. 219 
HPLC-FD METHOD 220 
System suitability test (SST) 221 
In this test the following parameters were calculated: retention factor (K), separation factor 222 
between two neighboring peaks (α), peak tailing factor and column efficiency (number of 223 
theoretical plates). The analysis was performed five times. Table 1 shows the results of the 224 
SST obtained from a control serum spiked with standard thujone at a concentration of 54.3 225 
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μg/mL.  The chromatographic system proved to be efficient and suitable for the quantification 226 
of thujone, with retention factor (K) ≥ 2, separation factor (α) > 1, and symmetry factor (SF) ≤ 227 
2. However, the method does not separate the two isomers of thujone, unlike gas 228 
chromatography, see below. 229 
Linearity 230 
Standard solutions (0.724 mg/mL) were added to a “blank” serum to the final concentration of 231 
14.5, 29.0, 58.0 and 72.4 g/mL and were prepared as previously described; each solution 232 
was analyzed at least three times. 233 
A linear regression was obtained by plotting the areas of analyte peaks vs. the nominal 234 
concentrations. The method was linear between 14.5 and 72.4 g/mL, with a correlation 235 
coefficient (R2) of >0.99. The linear regression equation was y = 253 137x – 189 570, where y 236 
refers to the peak area and x refers to concentration. 237 
Sensitivity (LOD and LOQ) 238 
The limit of detection (LOD) and the limit of quantitation (LOQ) were determined by spiking 239 
control serum with decreasing concentrations of thujone standard solutions: LOD was 240 
established at a signal-to-noise ratio of 3, while LOQ at a signal-to-noise ratio of 10. 241 
Furthermore, the precision at LOQ was evaluated with five independent injections. 242 
The LOD and LOQ calculated in spiked serum calibration samples were 1.36 g/mL and 4.53 243 
g/mL, respectively. The precision at LOQ was 19.4%, below the acceptable value of 20%. 244 
All values reported above were suitable for an accurate determination of thujone in serum 245 
samples. 246 
Selectivity 247 
The possible interaction between analytes and endogenous matrix (serum) compounds was 248 
investigated by adding standard thujone to a control serum at the final concentration of 54.3 249 
g/mL. Selectivity requires that the peak area of compounds eluting together with the analyte 250 
of interest is less than 20% of the peak area of sample at LOQ. As shown in Figure 2, 251 
thujone is clearly identified, since no significant peak was present at its retention time. The 252 
two isomers are not separated by HPLC; they are shown to have slightly different retention 253 
times in gas chromatography, as shown below. 254 
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Accuracy and precision 255 
Accuracy and precision were determined by spiking control serum with two quantities of 256 
purified thujone, at final concentrations of 18.1 and 54.3 g/mL. Accuracy describes the 257 
closeness of a measurement to the true value and is calculated as the percentage ratio 258 
between the experimentally measured values and the nominal ones. Precision was 259 
determined by calculating the variation coefficient (RSD%) of the peak areas of five replicates 260 
injected in the same day. The method was precise and accurate, since RSD% was below 261 
15% (5.1-5.7%) and the calculated accuracy was always within ±15% (106.8 to 108.5) of the 262 
nominal concentration. 263 
Recovery  264 
To evaluate the recovery in biological fluids, control serum was spiked with a standard 265 
solution at the final concentration of 25 g/mL. Recovery was 94.2±10.3%.  266 
 267 
Quantification of thujone in patient’s serum  268 
The chromatograms of the patient’s serum at day 0 and day 1 are illustrated in Figure 3. 269 
Using the regression line prepared in serum, thujone concentrations were determined and 270 
corresponded to 27.7±3.5 and 24.1±0.15 g/mL (mean ± SD), at day 0 and 1, respectively. 271 
The identification of thujone was confirmed by spiking the serum with a solution of purified 272 
standard (Figure 4).  273 
Quantification of thujone in patient’s urine 274 
The method was similarly validated for the analysis of urine, by using a linear regression 275 
obtained by spiking control urine with known quantities of purified standard. Figure 5 shows 276 
the chromatograms of a control urine without and with addition of a standard solution of 277 
thujone at a final concentration of 72.4 g/mL. 278 
No interfering peaks were present at the retention time of thujone in the control sample. No 279 
peak at the retention time of thujone was detectable (<LOD) in the patient’s urine (not shown). 280 
GC-FID METHOD 281 
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To confirm unambiguously the presence of thujone in the patient's biological fluids, the 282 
method of Dybowski and Dawidowicz (2016) was also applied. An example of the gas-283 
chromatographic separation of the two stereoisoforms of thujone and the internal standard 284 
naphthalene is illustrated in Figure 6.  285 
A calibration curve was obtained plotting the ratio between the area of the analyte and that of 286 
the internal standard (ISTD, naphthalene) vs. the respective concentrations. Within the 287 
concentrations used, the linearity was highly satisfactory, having R2 > 0.999 for both thujone 288 
isomers. 289 
The limit of detection (LOD) was calculated at a signal-to-noise ratio of 3 and LOQ at a signal-290 
to-noise ratio of 10. The latter was obtained by comparing the area of thujone signals and that 291 
of six peaks (average) of baseline noise from four injections of extracts (dichloromethane) of 292 
control serum samples spiked with a standard solution of thujone. LOD and LOQ were 0.11 293 
g/mL and 0.37 g/mL, respectively, for α-thujone, and 0.10 g/mL and 0.34 g/mL, 294 
respectively, for β–thujone. 295 
To evaluate the recovery in biological fluids, the control serum was spiked with standard 296 
thujone to a concentration of 25 g/mL (α = 23.0 g/mL, β = 4.2 g/mL) and injected.  The 297 
results showed an average value of 20.5±1.1 g/mL (α =15.5±0.9 g/mL, β = 2.8±0.16 298 
g/mL). The recovery was acceptable, being close to 82% for both total thujone and 299 
separated stereoisomers.  300 
Figure 7 shows the gas-chromatogram of the patient's serum at day 0, when the total thujone 301 
concentration was: 22.3±1.3 g/mL (α =18.9±1.0 g/mL, β = 3.4 ± 0.2 g/mL). In agreement 302 
with the HPLC method, no thujone could be detected in urine (< LOD) (not shown). 303 
 304 
DISCUSSION 305 
The case reported in this paper describes a patient who experienced a manic state after the 306 
consumption of an infusion of Artemisia vulgaris. The patient reported having consumed 307 
similar infusions for at least three years with no adverse effect. No neurotoxic effect related to 308 
Artemisia vulgaris derivatives could be found in the scientific literature, not surprisingly in view 309 
of the small amount of thujone in this species (Abad et al. 2012). Neurotoxic effects have 310 
been reported only for the essential oils of Artemisia absinthium, which contain significantly 311 
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higher amounts of thujone (Lachenmeier et al. 2006). On the other hand, the symptoms 312 
described by the first-aid physicians attending this patient were identical with those 313 
associated with thujone intoxication by Lachenmeier et al. 2006 and  Pelkonen et al. 2013). 314 
Although the presence of thujone in essential oils and in alcoholic extracts is well documented, 315 
aqueous extracts have been considered safe because of the low water solubility of this 316 
neurotoxic compound (Capasso, Grandolini, and Izzo, 2006).  317 
To confirm the presence of thujone in this patient's serum and urine, two analytical 318 
approaches were used: 1) an HPLC-FLD method, set up and validated for this study; and 2) 319 
the gas-chromatographic method using a flame ionization detector (FID) published by 320 
Dybowski and Dawidowicz (2016). 321 
For gas chromatography, the sample preparation was slightly modified from the original 322 
method since the biological fluids most usually obtained in the emergency room are serum 323 
and urine, and values measured in these fluids could be underestimated, because the fraction 324 
bound to plasma proteins would not be taken into account 325 
Although slightly different in performances (HPLC gives superior recovery, but shows lower 326 
sensitivity), both methods were considered useful in the identification and quantification of 327 
thujone in the case reported. With both methods, the concentration of total thujone in serum 328 
at day 0 was close to 25 g/mL confirming the intake of this molecule with the infusion. The 329 
differences in recovery could account for the small difference in serum concentrations 330 
obtained by the two methods (27.7 and 22.3 g/mL, by HPLC and GC, respectively). With 331 
both methods, thujone was below LOD when measured in urine. Since the raw material 332 
(herbal mixture) and the infusion were not available for further analytical assessments, it is 333 
only possible to hypothesize the following: 334 
1) An unusually high concentration of thujone in the Artemisia vulgaris. Even though 335 
there is no direct correlation between solubility in water and oil, a recent paper 336 
showed that the content of thujone in essential oil can vary significantly (Obistioiu et 337 
al. 2014). 338 
2) The patient has a low metabolic efficiency, which increases the half-life of 24 hours 339 
determined by Lis-Balchin et al. (2006). The very similar levels of thujone in the 340 
patient’s serum at day 0 and day 1 supports this hypothesis.  341 
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3) Thujone poisoning due to the chronic exposure (three years). Chronic toxicity of 342 
thujone has been described in rats and mice, which experienced clonic and tonic 343 
seizures and increased incidence of non-neoplastic lesions in brain, spleen, kidney 344 
and pituitary gland after two years of α,β-thujone intake (NTP, 2011); 345 
4) Possible adulteration/contamination of the Artemisia vulgaris with other species, e.g. 346 
Artemisia absinthium.  347 
To our knowledge, this is the first study where thujone was measured in human serum after a 348 
case of poisoning. Other quantifications in human serum have been reported in studies 349 
performed on volunteers (Kröner, Padosch, Lachenmeier, and Madea, 2005; Dybowski and 350 
Dawidowicz 2016).  351 
Kröner et al. (2005) described a pilot study in which two subjects consumed 110 mL of 352 
absinthe containing 3.85 mg thujone within 15 min; thujone was undetectable in their blood 353 
(LOD: 0.34 ng/mL). Dybowski and Dawidowicz (2016) detected thujone in plasma from five 354 
volunteers one hour after the consumption of an alcoholic solution containing approximately 355 
300 g of α,β-thujone. Plasma values ranged from 22.3 to 37.6 ng/g. Comparing the values 356 
found in our patient's serum (g/mL) with those measured in volunteers' serum (ng/mL), it is 357 
evident that our patient had been exposed to very high doses of thujone, during his long-term 358 
intake (daily for three years) with chronic accumulation of thujone, which is lipophilic. 359 
 360 
CONCLUSION 361 
This paper describes the first case of poisoning due to Artemisia vulgaris, in which thujone 362 
was identified as a biomarker of toxicity caused by prolonged excessive exposure. The case 363 
points out some general critical issues related to the consumption of botanicals. The 364 
increased use of botanicals/herbs in recent years is not always associated with suitable 365 
quality and safety control. There is a general belief by consumers that “natural” is always safe, 366 
but adverse effects of botanicals are far from rare.  367 
The case also allowed the comparison of two different analytical approaches to measure 368 
thujone in serum and urine. The method developed for this study (HPLC-FLD) proved to be 369 
simple, relatively cheap and sensitive enough to measure small quantities of thujone, as in a 370 
case of poisoining.  371 
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Table 1 - System suitability test for thujone (n = 5) 499 
tRa (min) 
(mean  SD) 
Kb 
(mean  SD) 
c 
(mean  SD) 
SFd 
(mean  SD) 
Ne 
(mean  SD) 
18.22  0.05 12.84  2.54 1.29  0.01 0.97  0.02 10316  405 
LEGEND: 500 
a tR = Retention time; b K (Retention factor) = (tR − t0)/t0, where tR and t0 are retention times 501 
of thujone and solvent, respectively;   c (Separation factor)= (tR − t0)/(tR1 − t0), where tR 502 
and tR1 are retention times of thujone and a neighboring peak, respectively; dSF (symmetry 503 
factor) = W0.05/2f, where W0.05 is width of the peak at 5% height and f the distance from the 504 
peak maximum to the leading edge of the peak, the distance being measured at a point 5% of 505 
the peak height from the baseline. e N (number of theoretical plates) = 16/(tR/W)2, where W is 506 
the peak width at its base. 507 
 508 
